Skip to menu Skip to content Skip to footer
Dr Yoon An
Dr

Yoon An

Email: 

Overview

Background

Dr Yoon-Kyo An is the “Head of Inflammatory Bowel Disease (IBD)” at Mater Hospital Brisbane and the “Clinical Lead of the IBD Clinical Trials Unit” at Mater Research, a world class centre of clinical and research excellence. The centre is among the largest IBD clinical research units in Australia. She is also a gastroenterologist who specialises in IBD, combining public and private practices at Mater Hospital Brisbane, Mater Private Hospital Brisbane, and Mater Private Hospital Redland. She holds a senior lecturer position at the University of Queensland. Dr An is a co-founder of digital healthcare education platform ‘GutTalk’, which aims to empower patients and communities by closing the communication and knowledge gap in Gut Health.

Dr An completed her Medical Science degree (BMedSc) at the University of Sydney and her Medical degree (MBBS) at the University of Queensland. She undertook her physician and advanced gastroenterology training at the Royal Brisbane and Women’s Hospital and Mater Hospital Brisbane. She completed a clinical and research fellowship in IBD at Mater Hospital Brisbane and completed the executive business and leadership program at the University of Oxford Said Business School. She is currently pursuing a PhD through the University of Queensland and an MBA through Griffith University.

Dr An is a passionate advocate for optimising patient outcomes through a holistic approach to care including personalised treatment plans to manage digestive health and incorporation of clinical and translational research. She is an active IBD clinician and researcher as well as a patient advocate. Her own research focusses on real-world effectiveness of biologic therapy in IBD and the use of intestinal ultrasound to monitor disease activity and predict responses to therapy. She drives collaborative research projects throughout Australia and is actively involved with the Australia New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC), the Gastroenterology Network for Intestinal Ultrasound (GENIUS) and the Gastroenterological Society of Australia (GESA).

Dr An has been successful in competitive research funding from industry and philanthropic organisations. She was the recipient of the inaugural GENIUS fellowship. She has affiliations with many Gastroenterology and IBD societies and has a national presence through her numerous symposia and conference presentations. She also serves on several Medical Advisory Boards including Chiesi, Bristol-Myers Squibb, and NPS Medicine Wise as well as sitting on the Council of Therapeutic Advisory Group. She is a GESA representative on the GP Aware Program committee and works collaboratively with Crohn’s and Colitis Australia (CCA).

Current Appointments

  • 2021 – current: Executive Committee Member – Secretary, ​​​​​​​​​​​​​​ Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC)
  • 2020 – current: Scientific Committee Member, Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC)
  • 2020 – current: Board Member – Research Officer, Gastroenterology Network for Intestinal Ultrasound (GENIUS)
  • 2020 – current: Executive Committee Member – IBD Liaison Officer, Young GESA Network, Gastroenterological Society of Australia (GESA)
  • 2020 – current: Expert Advisory Group member, The Council of Therapeutic Advisory Groups (CATAG)
  • 2020 – current: GESA representative, CCA-GESA GP Aware Program Committee, Crohn’s and Colitis Australia (CCA)
  • 2020 – current: Expert Working Group Member, bDMARDs Gastroenterology Design Forum, NPS Medicine Wise
  • 2020 – current: Stakeholder Panel (GESA representative), Value in Prescribing bDMARDs Program, NPS Medicine Wise

Availability

Dr Yoon An is:
Available for supervision

Works

Search Professor Yoon An’s works on UQ eSpace

77 works between 2011 and 2025

21 - 40 of 77 works

2024

Journal Article

Ustekinumab as induction and maintenance therapy for ulcerative colitis - national extended follow-up and a review of the literature

Chetwood, J. D., Gupta, S., Subramaniam, K., De Cruz, P., Moore, G., An, Y. K., Connor, S. J., Kermeen, M., Paramsothy, S. and Leong, R. W. (2024). Ustekinumab as induction and maintenance therapy for ulcerative colitis - national extended follow-up and a review of the literature. Expert Opinion on Drug Safety, 23 (4), 449-456. doi: 10.1080/14740338.2023.2278686

Ustekinumab as induction and maintenance therapy for ulcerative colitis - national extended follow-up and a review of the literature

2024

Journal Article

Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero

Prentice, Ralley, Flanagan, Emma, Wright, Emily K., Gibson, Peter R., Rosella, Sam, Rosella, Ourania, Begun, Jakob, An, Yoon-Kyo, Lawrance, Ian C., Kamm, Michael A., Sparrow, Miles, Goldberg, Rimma, Prideaux, Lani, Vogrin, Sara, Kiburg, Katerina V., Ross, Alyson L., Burns, Megan and Bell, Sally J. (2024). Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero. Clinical Gastroenterology and Hepatology, 23 (1), 124-133.e7. doi: 10.1016/j.cgh.2024.02.025

Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero

2024

Conference Publication

Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib

Gilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugpal, K., Han, S., Bryant, R., West, J., Segal, J., Christensen, B., Ding, N. J., An, Y. K. and Begun, J. (2024). Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.1194

Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib

2024

Conference Publication

Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial

Davies, J., Amiss, A., Khoo, E., An, Y. K. and Begun, J. (2024). Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0164

Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial

2024

Conference Publication

Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study

Kim, S. J., Kim, D. H., Park, S. H., Kim, K. O., Lee, Y. J., Song, E. M., Kim, E. S., Lee, H. S., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R., Liu, J., Cao, Q., Kobayashi, T. and Wei, S. C. (2024). Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0892

Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study

2024

Conference Publication

A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfaction

Fernandes, R., Khoo, E., Harris, H., Gilmore, R., Khaing, M., Begun, J., An, Y. K. and Mater IBD Research Group (2024). A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfaction. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0750

A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfaction

2024

Conference Publication

Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study

Kim, D. H., Park, S. H., Kim, H. S., Kim, S. J., Kim, K. O., Lee, Y. J., Song, E. M., Kim, E. S., Lee, H. S., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R., Liu, J., Cao, Q., Kobayashi, T. and Wei, S. C. (2024). Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0555

Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study

2024

Conference Publication

Preferences towards treatment attributes among patients with Crohn’s disease and ulcerative colitis in Argentina, Australia, Brazil, Saudi Arabia and Taiwan: a discrete choice experiment

Argollo, M., An, Y. K., Balderramo, D., Nahla, A., Kuo, C. J., Fadeeva, O. and Uy, E. (2024). Preferences towards treatment attributes among patients with Crohn’s disease and ulcerative colitis in Argentina, Australia, Brazil, Saudi Arabia and Taiwan: a discrete choice experiment. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0650

Preferences towards treatment attributes among patients with Crohn’s disease and ulcerative colitis in Argentina, Australia, Brazil, Saudi Arabia and Taiwan: a discrete choice experiment

2024

Conference Publication

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

Khoo, E., Amiss, A., Ding, J. N., Bryant, R., Mohsen, W., Connor, S., Leung, R., Croft, A., Lynch, K., Sparrow, M., De Cruz, P., An, Y. K., Holtmann, G. and Begun, J. (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0984

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

2023

Journal Article

Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment

Khoo, Emi, Lee, Andrew, Neeman, Teresa, An, Yoon‐Kyo and Begun, Jakob (2023). Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment. JGH Open, 7 (12), 899-907. doi: 10.1002/jgh3.13000

Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment

2023

Conference Publication

Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report

Etchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report

2023

Conference Publication

Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCC

Fernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Gazelakis, K., Moore, G., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Lynch, K., Ngoi, B., Judge, C., Kim, D. H., Kim, H. S., Lee, H. S., Kim, K. O., Lee, Y. J., Kim, S-J, Lee, J., Song, E. M., Park, S. H. ... An, Y-K (2023). Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCC. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCC

2023

Conference Publication

Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis

Gilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugopal, K., Han, S., Bryant, R., Corte, C., Ding, J. N., An, Y-K and Begun, J. (2023). Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis

2023

Conference Publication

Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trial

Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y-K, Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D., Chan, W., Mourad, F. and Leong, R. (2023). Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trial. HOBOKEN: WILEY.

Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trial

2023

Conference Publication

Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study

Etchegaray, A., Fernandes, R., Anandan, A. Shanmuga, Selvanathan, P., Malloy, R., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study

2023

Conference Publication

Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound

Fernandes, R., Harris, H., Khoo, E., Gilmore, R., Howlett, M., Walker, N., Hendy, P., Begun, J. and An, Y-K (2023). Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound

2023

Conference Publication

Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study

Anandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study

2023

Conference Publication

Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease

Tan, W. L., Barr, E., Pham, H., Fernandes, R., Khoo, E., An, Y-K and Begun, J. (2023). Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease

2023

Conference Publication

Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience

Gilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience

2023

Conference Publication

Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience

Tan, W. L., Gilmore, R., Huang, A., Fernandes, R., An, Y-K and Begun, J. (2023). Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience

Supervision

Availability

Dr Yoon An is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Dr Yoon An's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au